Aclaris Therapeutics develops novel product candidates for immuno-inflammatory diseases as a clinical-stage biopharmaceutical company. News about ACRS centers on clinical and corporate updates for ATI-052, an investigational anti-TSLP/IL-4Rα bispecific antibody; ATI-2138, an oral ITK/JAK3 inhibitor; and bosakitug (ATI-045), an anti-TSLP antibody program. Recurring updates include trial results and medical-meeting presentations in dermatology and inflammatory disease, development work in atopic dermatitis, lichen planus and asthma, financial results, R&D spending, royalty revenue from license agreements and healthcare conference presentations.
Aclaris Therapeutics (NASDAQ: ACRS) priced an underwritten offering expected to raise approximately $50.0 million in gross proceeds.
The offering comprises 7,785,714 common shares at $3.50 each and pre-funded warrants to purchase 6,500,000 shares at $3.49999 each, with a $0.00001 exercise price per share. All securities will be sold by Aclaris. Participants include TCGX, RA Capital Management, Invus and a large mutual fund. Aclaris expects closing on October 28, 2026, subject to customary closing conditions. Gross proceeds exclude underwriting discounts, commissions and other offering expenses payable by Aclaris.
Aclaris Therapeutics (ACRS) reported Phase 1b results for ATI-052 in atopic dermatitis and asthma, with both trials meeting their primary safety objective. The trials enrolled 14 and 16 patients, respectively. No Grade 3 or 4 treatment-emergent adverse events, adverse-event discontinuations or conjunctivitis were observed.
In atopic dermatitis, the day-57 mean improvement in the Eczema Area and Severity Index was 45% placebo-adjusted; itch improvement was 43% placebo-adjusted. In asthma, a single dose reduced exhaled nitric oxide, an airway inflammation marker, by 59% at day 15 versus 15% with placebo. Mean improvement in one-second exhaled air volume was 200 ml, both absolute and placebo-adjusted, at day 15. Aclaris intends to prioritize a Phase 2b trial in eosinophilic esophagitis early next year and update plans for a potential additional indication in the near term.
Aclaris Therapeutics (ACRS) will participate in a fireside chat at the 2026 Cantor Global Healthcare Conference in New York on September 10, 2026, at 2:45 PM ET.
The session will feature Chief Executive Officer Dr. Neal Walker. A live and archived webcast will be available on the Events page of the Aclaris website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) announced that the U.S. FDA has granted Fast Track Designation for its investigational therapy modzatinib (ATI-2138) for moderate to severe lichen planus (LP), including oral erosive LP, cutaneous LP, and lichen planopilaris.
According to Aclaris, Fast Track status enables more frequent FDA interactions, the possibility of rolling New Drug Application review, and potential eligibility for Priority Review if criteria are met. The company expects to initiate a phased, multi-part Phase 2b LP trial in the fourth quarter of 2026 as it advances its immuno-inflammatory pipeline.
Aclaris Therapeutics (NASDAQ: ACRS) reported second quarter 2026 net loss of $21.5 million versus $15.4 million a year earlier on total revenue of $1.6 million versus $1.8 million. R&D rose to $18.1 million, driven mainly by ATI-052 and ATI-9494 development, while G&A increased to $6.0 million.
Cash, cash equivalents and marketable securities were $170.6 million at June 30, 2026, up from $151.4 million at year-end 2025. After quarter-end, Aclaris raised $40.2 million gross via sale of 7.3 million shares under its ATM, and now expects its cash to fund operations through end of 2028. Clinically, full Phase 1a SAD/MAD data for bispecific antibody ATI-052 showed a favorable safety profile and PK/PD supporting potential quarterly dosing, and timelines were reaffirmed for 2026 readouts from two Phase 1b POC trials of ATI-052 and a Phase 2 trial of anti-TSLP antibody bosakitug (ATI-045).
Aclaris Therapeutics (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on immuno-inflammatory diseases, will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York.
The event is scheduled for June 4, 2026 at 2:00 PM ET, with a live and archived webcast available on Aclaris’ website for at least 30 days.
Aclaris Therapeutics (NASDAQ: ACRS) will present at the 2026 Bank of America Healthcare Conference in Las Vegas on May 14, 2026 at 9:35 AM PT. Dr. Hugh Davis, President and COO, will deliver the corporate presentation. A live and archived webcast will be available on the company website for at least 30 days.
Aclaris (NASDAQ: ACRS) reported Q1 2026 results and clinical updates on May 7, 2026. Key clinical highlights include positive Phase 1a SAD/MAD results for bispecific antibody ATI-052 with an estimated half-life ~45 days and sustained PD through week 20 in the 480 mg cohort. The company completed bosakitug Phase 2 enrollment (109 patients) and plans Phase 2b for ATI-052 and an IND for ATI-9494 in H2 2026. Financially, cash and investments totaled $190.8M at March 31, 2026; the company expects runway through end of 2028. Q1 net loss was $19.8M.
Aclaris Therapeutics (NASDAQ: ACRS) reported positive full top-line Phase 1a SAD/MAD results for ATI-052, an anti-TSLP/IL-4Rα bispecific antibody, showing an estimated half-life of ~45 days and sustained PD activity supporting up to three-month dosing.
The company also selected lichen planus as the lead indication for oral ITK/JAK3 inhibitor ATI-2138 and plans Phase 2b programs in 2H 2026; Phase 1b ATI-052 trials in asthma and atopic dermatitis have top-line results expected in 2H 2026.
Aclaris Therapeutics (NASDAQ: ACRS) will release full Phase 1a results for its anti-TSLP/IL-4R bispecific antibody ATI-052 and announce lead indication selection for its ITK/JAK3 inhibitor ATI-2138 before markets open on April 28, 2026.
The company will host a webcast and conference call with slides on April 28, 2026 at 8:30 AM EST; the live and archived webcast will be available on the company Events page and archived for 30 days.